Li Yuecui, Li Chenghang, Fang Yu, Zhang LiLi, Ying Xiaoyan, Ren Ruotong, Zang Yinghui, Ying Dandan, Zhu Shengwei, Liu Jiao, Cao Xuefang
Department of Infectious Disease, The First People's Hospital of Yongkang, affiliated to Hangzhou Medical College, Jinhua, People's Republic of China.
Zhejiang Key Laboratory of Digital Technology in Medical Diagnostics, Hangzhou, People's Republic of China.
Infect Drug Resist. 2025 May 2;18:2215-2227. doi: 10.2147/IDR.S504587. eCollection 2025.
BACKGROUND: This study aimed to investigate the co-infecting pathogens and lung microbiomes in patients with clinically confirmed pulmonary tuberculosis (TB) and explore potential diagnostic biomarkers to differentiate between varied infection patterns. METHODS: We conducted a retrospective cohort study by analyzing 198 bronchoalveolar lavage fluid (BALF) samples collected from patients with suspected pulmonary TB. All BALF samples were sequenced using metagenomic next-generation sequencing (mNGS). RESULTS: A total of 63 pathogens were detected in all samples. The TB group exhibited a higher diversity of pathogens (n=51) than the Non-TB group (n=37). The analysis revealed that TB patients had significantly higher pathogen counts (=0.014), and specific microorganisms, such as complex (MTBC), MTB, , and , were significantly enriched. Furthermore, the abundance of MTBC was negatively correlated with hemoglobin levels (R=-0.17, =0.015) and positive correlated with C-reactive protein (CRP) levels (R=0.16, =0.029). The random forest model combined eight differential microbes and five clinical parameters, yielding an area under the curve (AUC) of 0.86 for differentiating TB from Non-TB cohorts, whereas subgroup differentiation yielded an AUC of 0.571, demonstrating the potential for targeted diagnostics in pulmonary infections. CONCLUSION: Our findings highlight the complexity of co-infection patterns in pulmonary TB and emphasize the potential of integrating microbial and clinical markers to improve diagnostic accuracy. This study provides valuable insights into the role of the lung microbiome in TB and informs future research on targeted therapies for this disease.
Biology (Basel). 2024-1-27
Front Immunol. 2023
J Clin Med. 2022-9-30